



# **NEXUS Surgical And Medicare Limited**

Regd. Address: Gala No. 4, Building No. 1, Saarthak, Square Ind Park, Sativali,  
Vasai (East), Palghar - 401 208. | Tel.: 8433598185 | Email: nexuscomm92@gmail.com  
Website: www.nexusmed.co.in | CIN: L33100MH1992PLC328367

Date: 21<sup>st</sup> January, 2025

To,  
BSE Limited  
Corporate Relation Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001.

**Script Code - 538874**

**Sub: Outcome of Board Meeting held on Tuesday, 21<sup>st</sup> January, 2025**

Dear Sir / Madam,

We would like to inform you that the meeting of the Board of Directors of **Nexus Surgical and Medicare Limited** was held on **Tuesday, 21<sup>st</sup> January, 2025 at 03:30 p.m.** at the Registered Office of the Company situated at Gala No. 4, Saarthak, Building No. 1, Square Industrial Park, Tungarphata, Vasai (East), Palghar - 401 208 and transacted the following business:

1. The Board of Directors of the Company has approved the unaudited quarterly financial results of the Company for the quarter ended 31<sup>st</sup> December, 2024. A copy of the same alongwith Limited Review Report on the said results is enclosed herewith.

The meeting commenced at 03:30 p.m. and concluded at 05:30 p.m.

Kindly take the same on your records.

Thanking you.

Yours faithfully,

**For Nexus Surgical and Medicare Limited**

**Ram Swaroop Joshi**

**DIN: 07184085**

**Managing Director**

**Encl.: as above**

## Nexus Surgical and Medicare Limited

### Statement of Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2024

(Rs. in lakhs, except earning per share data)

Particulars	Quarter Ended on			Nine Months Ended on		Year Ended
	Dec 31, 2024 (Unaudited)	Sep 30, 2024 (Unaudited)	Dec 31, 2023 (Unaudited)	Dec 31, 2024 (Unaudited)	Dec 31, 2023 (Unaudited)	March 31, 2024 (Audited)
<b>Income</b>						
Sales	148.39	99.49	144.60	423.91	287.63	347.42
Other Income	-	-	0.55	-	3.15	2.68
<b>Total Income</b>	<b>148.39</b>	<b>99.49</b>	<b>145.15</b>	<b>423.91</b>	<b>290.78</b>	<b>350.11</b>
<b>Expenses</b>						
Purchase of stock-in-trade	63.30	62.98	21.48	147.39	50.92	92.51
Change in inventories of stock-in-trade	(33.89)	(26.28)	0.03	(25.75)	(13.11)	(33.15)
Employee benefits expense	4.87	4.87	7.19	15.25	18.06	23.99
Depreciation and amortization expense	0.10	0.10	0.06	0.30	0.13	0.19
Other expense	98.83	30.31	110.17	232.04	214.00	237.49
<b>Total Expenses</b>	<b>133.21</b>	<b>71.98</b>	<b>138.93</b>	<b>369.23</b>	<b>269.99</b>	<b>321.04</b>
<b>Profit/(loss) before Exceptional Item and Tax</b>	<b>15.17</b>	<b>27.51</b>	<b>6.22</b>	<b>54.67</b>	<b>20.78</b>	<b>29.07</b>
Exceptional Item Income/(Loss)	-	-	-	-	-	-
<b>Profit/(loss) before tax</b>	<b>15.17</b>	<b>27.51</b>	<b>6.22</b>	<b>54.67</b>	<b>20.78</b>	<b>29.07</b>
Current Tax	3.82	6.94	1.57	13.76	5.23	7.70
Tax for earlier years	-	-	-	-	-	(0.08)
Deferred Tax	-	-	(0.00)	-	0.06	0.12
<b>Tax expenses</b>	<b>3.82</b>	<b>6.94</b>	<b>1.57</b>	<b>13.76</b>	<b>5.29</b>	<b>7.74</b>
<b>Profit/(loss) for the period</b>	<b>11.36</b>	<b>20.56</b>	<b>4.66</b>	<b>40.91</b>	<b>15.49</b>	<b>21.33</b>
<b>Other comprehensive income (OCI), net of income tax</b>						
Items that will not be reclassified to profit or loss	-	-	-	-	-	-
Items that will be reclassified to profit or loss	-	-	-	-	-	-
Total other comprehensive income, net of income tax	-	-	-	-	-	-
<b>Total other comprehensive income for the period</b>	<b>11.36</b>	<b>20.56</b>	<b>4.66</b>	<b>40.91</b>	<b>15.49</b>	<b>21.33</b>
Paid-up Equity Share Capital (Equity shares of Rs. 10 each)	547.19	547.19	547.19	547.19	547.19	547.19
<b>Other Equity</b>						(490.56)
Basic and Diluted Earning Per Share (not annualized)	0.21	0.38	0.09	0.75	0.28	0.39

#### Notes:

- The above Unaudited Financial result have been reviewed and recommended by the audit committee and have been approved by the Board of Directors at their meeting held on January 21, 2025. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The aforesaid unaudited financial results for the quarter and nine months ended December, 31,2024 have been prepared in accordance with Companies (Indian Accounting Standard) Rule, 2015 as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of Regulation 33 of SEBI (Listing Obligation and disclosure Requirements ) Regulations, 2015, as amended.
- The Company is engaged primarily in the trading business and accordingly there are no separate reportable segments as per Ind AS 108 dealing with Operating Segment.
- Previous period figures have been restated or regrouped or rearranged wherever necessary, to make them comparable.
- The company has not received any shareholder / investors complaints during the quarter ended December 31, 2024.

For and on behalf of Board of Directors of  
Nexus Surgical and Medicare Limited

Ram Swaroop Joshi  
Managing Director  
DIN: 07184085

January 21, 2025



## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

To  
The Board of Directors  
**Nexus Surgical and Medicare Limited**


We have reviewed the accompanying Statement of unaudited standalone financial results of **Nexus Surgical and Medicare Limited ("the Company")** for the quarter ended December 31, 2024 and for the period from April 01, 2024 to December 31, 2024, ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of  
**Satya Prakash Natani & Co.**  
**Chartered Accountants**  
Firm's Registration No.: 115438W



**Satya Prakash Natani**  
**Partner**

Membership No.: 048091

Mumbai

Date: January 21, 2025

UDIN : 25048091BMKQIK4282

**Office:** 505, Goyal Trade Center, Sona Cinema, Shantivan, Borivali (E), Mumbai-400 066.

Tel.: 2897 6621 Email: [spnatani@gmail.com](mailto:spnatani@gmail.com) Web.: [www.casprnatani.in](http://www.casprnatani.in)